In our study, however, a significant negative effect on survival in presence of IDO in ≥10% and <50% of tumor cells was found (Supplementary Table S2, median survival 19 months (CI: 12.4–25.6) vs. 4 months (CI: 0.0–13.2), p = 0.016). Here, IDO1 is linked to neoplasm.